CO2021005207A2 - Métodos de tratamiento - Google Patents

Métodos de tratamiento

Info

Publication number
CO2021005207A2
CO2021005207A2 CONC2021/0005207A CO2021005207A CO2021005207A2 CO 2021005207 A2 CO2021005207 A2 CO 2021005207A2 CO 2021005207 A CO2021005207 A CO 2021005207A CO 2021005207 A2 CO2021005207 A2 CO 2021005207A2
Authority
CO
Colombia
Prior art keywords
treatment methods
methods
cancer
compositions
tumor antigens
Prior art date
Application number
CONC2021/0005207A
Other languages
English (en)
Inventor
Jessica Baker Flechtner
Marie Lossky-Elias
Pamela M Carroll
Hubert Lam
Lisa K Mcneil
Wendy Jane Broom
Original Assignee
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genocea Biosciences Inc filed Critical Genocea Biosciences Inc
Publication of CO2021005207A2 publication Critical patent/CO2021005207A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se proporcionan métodos y composiciones para identificar antígenos tumorales de linfocitos humanos y para tratar sujetos que tienen cáncer.
CONC2021/0005207A 2018-09-27 2021-04-22 Métodos de tratamiento CO2021005207A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737862P 2018-09-27 2018-09-27
PCT/US2019/053669 WO2020069452A1 (en) 2018-09-27 2019-09-27 Treatment methods

Publications (1)

Publication Number Publication Date
CO2021005207A2 true CO2021005207A2 (es) 2021-07-30

Family

ID=69953226

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0005207A CO2021005207A2 (es) 2018-09-27 2021-04-22 Métodos de tratamiento

Country Status (14)

Country Link
US (1) US20230041057A1 (es)
EP (1) EP3856207A4 (es)
JP (1) JP2022502433A (es)
KR (1) KR20210091137A (es)
CN (1) CN113194967A (es)
AU (1) AU2019351273A1 (es)
BR (1) BR112021005596A2 (es)
CA (1) CA3113259A1 (es)
CO (1) CO2021005207A2 (es)
EA (1) EA202190862A1 (es)
IL (1) IL281792A (es)
MX (1) MX2021003262A (es)
SG (1) SG11202102878TA (es)
WO (1) WO2020069452A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2578394A (en) 2017-08-07 2020-05-06 Univ California Platform for generating safe cell therapeutics
IL293350A (en) * 2019-11-27 2022-07-01 Myst Therapeutics Llc A method for producing tumor-reactive t cells using modulatory substances
CN113278731A (zh) * 2021-05-12 2021-08-20 广西医科大学 用于判断HIV-1感染者抗病毒治疗效果的lncRNA标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) * 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
CN1902488A (zh) * 2003-11-13 2007-01-24 健泰科生物技术公司 肿瘤治疗的筛选实验和方法
US7754482B2 (en) * 2004-05-27 2010-07-13 The Trustees Of The University Of Pennsylvania Artificial antigen presenting cells and uses therefor
DE602006017556D1 (de) * 2005-08-05 2010-11-25 Helmholtz Zentrum Muenchen Erzeugung allorestriktiver spezifischer t-zellen
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
CN105979961B (zh) * 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
TWI742008B (zh) * 2015-11-02 2021-10-11 美商健生生物科技公司 使用特異性結合ｃｄ３８之抗體免疫調節及治療固態腫瘤

Also Published As

Publication number Publication date
IL281792A (en) 2021-05-31
AU2019351273A1 (en) 2021-05-20
WO2020069452A1 (en) 2020-04-02
EP3856207A4 (en) 2022-11-16
BR112021005596A2 (pt) 2021-06-29
MX2021003262A (es) 2021-07-15
CN113194967A (zh) 2021-07-30
EP3856207A1 (en) 2021-08-04
KR20210091137A (ko) 2021-07-21
CA3113259A1 (en) 2020-04-02
JP2022502433A (ja) 2022-01-11
EA202190862A1 (ru) 2021-07-07
SG11202102878TA (en) 2021-04-29
US20230041057A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
MX2019011148A (es) Metodos de tratamiento.
CO2021005207A2 (es) Métodos de tratamiento
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
BR112018015485A2 (pt) imunoglobulina fabs-in-tandem e usos da mesma
GT201700286A (es) Modulación y tratamiento inmunes de tumores sólidos con anticuerpos que se unen específicamente a cd38
PE20210289A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
BR112016022345A2 (pt) terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
BR112016005303A2 (pt) anticorpos anti-b7-h1 para tratamento de tumores
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
CO2021005234A2 (es) Métodos de tratamiento
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
WO2017040666A3 (en) Combination therapy for treatment of disease
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.